Prader-Willi Syndrome Clinical Trial
— DBSPWOfficial title:
Phase 1 Study of Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome
The purpose of this study is to investigate the safety and efficacy of deep brain stimulation in obese patients with Prader Willi syndrome refractory to conventional treatment.
Status | Recruiting |
Enrollment | 6 |
Est. completion date | October 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 15 Years and older |
Eligibility |
Inclusion Criteria: - 15 years or older - Parents able to give informed consent - Diagnosis of Prader-Willi syndrome confirmed by genetic analysis - Refractoriness to medical treatment, defined as a weight loss lower than 10% of the body weight with nutritional, pharmacological or surgical interventions - Severe or morbid obesity - No contra-indications to the surgical procedure Exclusion Criteria: - Cardiovascular disease that might significantly increase the surgical risk - Brain lesions detected clinically or during MRI - Use of cardiac pacemakers/ defibrillators - Clinical conditions that may require the use of MRI in the post-operative period - Patients undergoing chemotherapy or immunosuppressive treatments - Patients unable to return to the hospital at the required intervals - Previous neurosurgical treatments that may increase the risk of DBS surgery - Active medical conditions that may require in-hospital treatment in the nearby future - Previous diagnosis of epilepsy or status epilepticus - Chronic infection - Plan to use diathermy - Metallic implants that might preclude MRI imaging of the brain - Active participation in other experimental studies |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Brazil | HCFUMSP | Sao Paulo | SP |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo General Hospital |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | waist circumference; mid-upper arm circumference | 6 months | No | |
Primary | resting energy expenditure | 6 months | No | |
Primary | Body mass index | 6 months | No | |
Primary | Number of Participants with Adverse Events as a Measure of Safety and Tolerability | 3 months | Yes | |
Primary | Number of Participants with Adverse Events as a Measure of Safety and Tolerability | 6 months | Yes | |
Secondary | daily food ingestion diary listing | 6 months | No | |
Secondary | Child Yale-Brown Obsessive Compulsive Scale | 6 months | No | |
Secondary | Child Behaviour Checklist | 6 months | No | |
Secondary | Feeding Behaviour Questionnaire | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05032326 -
Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial
|
Phase 3 | |
Completed |
NCT04526379 -
Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation
|
N/A | |
Terminated |
NCT03458416 -
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
|
Phase 2 | |
Completed |
NCT03718416 -
Natural History Study of Serious Medical Events in PWS
|
||
Completed |
NCT05322096 -
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
|
Phase 2 | |
Completed |
NCT02205450 -
Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell
|
||
Terminated |
NCT02179151 -
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
|
Phase 3 | |
Completed |
NCT00375089 -
Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity
|
N/A | |
Completed |
NCT00004351 -
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
|
N/A | |
Recruiting |
NCT05938543 -
Cerebellar TMS and Satiety in Prader-Willi Syndrome
|
N/A | |
Suspended |
NCT05879614 -
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
|
Phase 2 | |
Recruiting |
NCT03031626 -
Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome
|
Phase 4 | |
Withdrawn |
NCT04086810 -
An Open-Label Study of DCCR Tablet in Patients With PWS
|
Phase 3 | |
Completed |
NCT02629991 -
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT02263781 -
PREPL in Health and Disease
|
N/A | |
Completed |
NCT00551343 -
Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome
|
N/A | |
Recruiting |
NCT06448871 -
Ultrasound to Assess Sarcopenia in Prader Willi Syndrome
|
||
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT05939453 -
Impact of Bright Light Therapy on Prader-Willi Syndrome
|
N/A | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|